Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer—Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control-Reference-Cited by-同舟云学术

Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer—Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control

Published:2019-01 Issue:1 Volume:18 Page:8-12
ISSN:1538-4721
Container-title:Brachytherapy
language:en
Short-container-title:Brachytherapy

Author:

Schroeder Christoph,Geiger Friedemann,Siebert Frank-André,Baumann René,Bockelmann Gunnar,Schultze Jürgen,Kimmig Bernhard,Dunst Jürgen,Galalae Razvan

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference28 articles.

1. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes;Blasko;Semin Radiat Oncol,2002

2. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I (125) prostate brachytherapy in clinically localized prostate cancer: seattle experience;Sylvester;Int J Radiat Oncol Biol Phys,2011

3. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT consortium;Ishiyama;Brachytherapy,2017

4. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone?;Galalae;Brachytherapy,2014

5. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy;Martinez;Int J Radiat Oncol Biol Phys,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review;Biomedicines;2024-04-08

2. The clinical relative biological effectiveness and prostate‐specific antigen kinetics of carbon‐ion radiotherapy in low‐risk prostate cancer;Cancer Medicine;2022-07-19

3. Biochemical failure and toxicity in treatment with brachytherapy and external beam radiotherapy compared with radical prostatectomy in localized prostate cancer;Reports of Practical Oncology and Radiotherapy;2022-07-06

4. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients;Radiotherapy and Oncology;2019-12

5. Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience;Journal of Contemporary Brachytherapy;2019